이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Grand Pharmaceutical Group 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chao Zhou

최고 경영자

HK$1.9m

총 보상

CEO 급여 비율	90.8%
CEO 임기	3yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chao Zhou 의 보수는 Grand Pharmaceutical Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	HK$2m	HK$2m	HK$2b

보상 대 시장: Chao 의 총 보상 ($USD 239.97K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 486.88K ).

보상과 수익: Chao 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Chao Zhou (34 yo)

3yrs

테뉴어

HK$1,873,000

보상

Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...

리더십 팀

이름	위치	테뉴어	보상	소유권
Weikun Tang	Executive Chairman	3yrs	HK$2.89m	0.021% HK$ 3.4m
Chao Zhou	CEO & Executive Director	3yrs	HK$1.87m	0.010% HK$ 1.7m
Guang Yang	Executive Director	less than a year	HK$25.00k	데이터 없음
Liu Hu	Investor Relations Director	no data	데이터 없음	데이터 없음
Tin Chung Foo	Company Secretary	12.8yrs	데이터 없음	데이터 없음
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	데이터 없음	데이터 없음
Xiaojie Chen	Vice President	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: 512 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Weikun Tang	Executive Chairman	3yrs	HK$2.89m	0.021% HK$ 3.4m
Chao Zhou	CEO & Executive Director	less than a year	HK$1.87m	0.010% HK$ 1.7m
Guang Yang	Executive Director	less than a year	HK$25.00k	데이터 없음
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	데이터 없음	데이터 없음
Tosi Wan So	Independent Non-Executive Director	19.3yrs	HK$180.00k	데이터 없음
Yebi Hu	Independent Non-Executive Director	5.5yrs	HK$60.00k	데이터 없음
Geng Pei	Independent Non-Executive Director	13.1yrs	HK$100.00k	데이터 없음
Guofan Xie	Director of Grand Pharm (China)	30.4yrs	데이터 없음	데이터 없음
Zhang Bangguo	Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited	no data	데이터 없음	데이터 없음
Li Xing	Non-Executive Director	no data	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: 512 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Grand Pharmaceutical Group 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Executive Chairman recently bought HK$271k worth of stock

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought HK$371k worth of stock

Recent updates

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022)

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020)

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Less than half of directors are independent

Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million.

Executive Deputy Chairman Bo Hu has left the company

Executive Chairman Chengwei Liu has left the company

China Grand Pharmaceutical and Healthcare Holdings Limited Announces TLX591-CDx Dosed the First Patient in Japan

China Grand Pharmaceutical and Healthcare Holdings Limited Declares Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on June 1, 2021

Upcoming dividend of HK$0.11 per share

China Grand Pharmaceutical and Healthcare Holdings Limited to Introduce the New Generation Heartlight X3 Laser Ablation Platform of Heartlight Endoscopic Ablation System

Investor sentiment improved over the past week

China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) entered into an agreement to acquire Jiangsu Shenming Medical Technology Co., Ltd. for CNY 22.6 million.

Full year 2020 earnings released: EPS HK$0.52 (vs HK$0.35 in FY 2019)

China Grand Pharmaceutical and Healthcare Holdings Limited Announces Declaration of Final Dividend for the Year Ended December 31, 2020

China Grand Pharmaceutical and Healthcare Holdings Limited Recommends Final Dividend for the Year Ended December 31 2020, Payable on or About 23 June 2021

China Grand Pharmaceutical and Healthcare Holdings Limited, Annual General Meeting, Jun 01, 2021

Full year 2020 earnings released

New 90-day low: HK$6.06